Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemotherapy agent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    899 result(s) found for: Chemotherapy agent. Displaying page 1 of 45.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-004682-40 Sponsor Protocol Number: CBYL719K12301 Start Date*: 2021-06-16
    Sponsor Name:Novartis Pharma AG
    Full Title: EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single a...
    Medical condition: Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) PT (Completed) FI (Trial now transitioned) CZ (Completed) DK (Completed) SK (Completed) FR (Completed) NL (Completed) ES (Ongoing) DE (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004105-16 Sponsor Protocol Number: MO29872 Start Date*: 2017-12-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAÏVE ADVANCED OR RECURRENT (STAG...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) PT (Completed) PL (Completed) ES (Ongoing) IE (Completed) BE (Completed) SK (Completed) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-002932-18 Sponsor Protocol Number: 42756493-BLC3001 Start Date*: 2018-02-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
    Medical condition: Advanced Urothelial Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10077840 Urothelial cancer of renal pelvis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) HU (Completed) ES (Ongoing) AT (Completed) FR (Trial now transitioned) DE (Ongoing) NL (Ongoing) PT (Completed) GR (Completed) PL (Completed) IT (Completed) DK (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001944-21 Sponsor Protocol Number: PALO-03-14 Start Date*: 2005-09-23
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Multicenter, Phase III, Open-Label, Uncontrolled Study to Assess the Safety and Efficacy of a Single Oral Dose of Palonosetron 0.75 mg in the Prevention of Chemotherapy Induced Nausea and Vomiting ...
    Medical condition: Moderately emetogenic chemotherapy induced nausea and vomiting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-005003-41 Sponsor Protocol Number: 392MD/15/C Start Date*: Information not available in EudraCT
    Sponsor Name:Strakan Pharmaceuticals Ltd
    Full Title: A randomised, active control, double-blind, double-dummy, parallel-group, multi-national study to assess the efficacy, tolerability and safety of the granisetron transdermal delivery system (GTDS) ...
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with the administration of moderately or highly emetogenic multi-day chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003755-12 Sponsor Protocol Number: Start Date*: 2006-10-24
    Sponsor Name:Hull & East Yorkshire NHS Trust
    Full Title: A Randomised Phase III Study in Advanced Oesophageal Cancer to compare Quality of Life and Palliation of Dysphagia in Patients Treated with Radiotherapy versus Chemo-radiotherapy.
    Medical condition: Advanced oesophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000227-71 Sponsor Protocol Number: ITCC-059 Start Date*: 2016-09-02
    Sponsor Name:Erasmus Medical Center
    Full Title: A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
    Medical condition: pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) CZ (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) IT (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) PT (Prematurely Ended) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003564-72 Sponsor Protocol Number: Start Date*: 2012-01-13
    Sponsor Name:Aarhus University Hospital [...]
    1. Aarhus University Hospital
    2. Aarhus University Hospital
    Full Title: A Randomised phase II study with the combination of Xeloda (Capecitabine) plus Navelbine Oral ( Vinorelbine) day 1 and day 8 every 3. week versus Xeloda plus Navelbine Oral given metronimic as 1. o...
    Medical condition: Patient with relapse of breast cancer will be randomised for two different chemotherapy regimes ( 2 treatments arms)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011251-48 Sponsor Protocol Number: CNTO888PCR2001 Start Date*: 2009-08-28
    Sponsor Name:Janssen Biologics B.V.
    Full Title: An Open-label, Multicenter, Phase 2 Study of Single-agent CNTO 888 (an anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects with Metastatic Castrate-Resistant Prostate Cancer
    Medical condition: Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001783-34 Sponsor Protocol Number: MK-0517-044 Start Date*: 2015-08-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III, randomized, placebo-controlled clinical trial to study the efficacy and safety of MK-0517/fosaprepitant and ondansetron versus ondansetron for the prevention of chemotherapy-induced na...
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) ES (Completed) LT (Completed) FI (Completed) PT (Completed) EE (Completed) HU (Completed) GB (Completed) NL (Completed) GR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-018780-42 Sponsor Protocol Number: OMB113676 Start Date*: 2010-10-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
    Medical condition: Indolent B-Cell Non-Hodgkin's Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Prematurely Ended) BG (Prematurely Ended) BE (Completed) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-006259-12 Sponsor Protocol Number: 1814 Start Date*: 2012-09-03
    Sponsor Name:Jules Bordet Institute
    Full Title: Phase II study on prospective evaluating the quantification of total choline by magnetic resonance spectroscopy (MRS) in breast tumours as an early predictive marker of neoadjuvant chemotherapy res...
    Medical condition: Early breast cancer requiring neoadjuvant chimiotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002340-24 Sponsor Protocol Number: 0517-029 Start Date*: 2012-10-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for...
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10042613 - Surgical and medical procedures 10036899 Prophylaxis against chemotherapy induced vomiting LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) DE (Completed) AT (Completed) HU (Completed) EE (Completed) GB (Completed) LT (Completed) GR (Completed) IT (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000651-16 Sponsor Protocol Number: 0869-208 Start Date*: 2011-07-20
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention...
    Medical condition: Pediatric Chemotherapy induced nausea and vomiting (CINV)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10052401 Vomiting post chemotherapy LLT
    13.1 10017947 - Gastrointestinal disorders 10056989 Nausea post chemotherapy LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) PT (Not Authorised) LT (Completed) ES (Completed) NL (Completed) DK (Completed) HU (Completed) SI (Completed) GR (Completed) GB (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-005816-29 Sponsor Protocol Number: 2006-002-0201-ONC Start Date*: 2008-06-17
    Sponsor Name:Royal Wolverhampton Hospitals Trust
    Full Title: A Pilot Study of Taxotere (Docetaxel), Cisplatin and 5FU (TPF) in the Palliative Treatment of Squamous Cell Carcinoma of the Head and Neck
    Medical condition: Locally recurrent or metastatic squamous call carcinoma of the head and neck
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002417-36 Sponsor Protocol Number: CAPTEM Start Date*: 2014-08-28
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: An open-label, randomized, multicenter, phase II trial designed to estimate the activity of CAPTEM combination versus FOLFIRI as second line treatment in patients who have progressed on or after fi...
    Medical condition: colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10008442 Chemotherapies HLT
    17.0 100000004867 10069759 KRAS mutation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000080-16 Sponsor Protocol Number: NeoToc Start Date*: 2016-07-21
    Sponsor Name:Vejle Hospital
    Full Title: Tocotrienol in combination with neoadjuvant chemotherapy for women with breast cancer
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-004471-13 Sponsor Protocol Number: PM1183-C-008-21 Start Date*: 2022-08-03
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relaps...
    Medical condition: Small Cell Lung Cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BG (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012595-27 Sponsor Protocol Number: A8081007 Start Date*: 2010-01-20
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (...
    Medical condition: ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed) PL (Completed) ES (Completed) HU (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed) BG (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002767-17 Sponsor Protocol Number: D0816C00020 Start Date*: 2017-12-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non-Germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Pa...
    Medical condition: Non Germline BRCA Mutated Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) SI (Completed) BG (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) AT (Completed) SE (Completed) PT (Completed) NO (Completed) DK (Completed) FI (Completed) PL (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 02:19:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA